New Brain Cancer Drug Shows Great Promise
One company in our portfolio looks like it will change the landscape for the most common form of brain cancer, glioblastoma multiforme. In the United States, this type of cancer appears in about 12,000 people annually.
It's one of the worst forms of cancer to get, since the cure rate is so low. Overall, most patients don't live to see a year and a half after diagnosis -- despite using the best therapies currently available. Fewer than one in four survive to three years, and perhaps one in 10 might survive to see a fifth anniversary of that date.
You Must Be A Subscriber To View This Content.
If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!
Technology Profits Confidential
With new technologies in mobile computing, biotechnology and 3-D printing, it’s nearly impossible to keep up with the throngs of new innovation and still be able to forecast which companies are set to profit. Technology Profits Confidential is your one-stop shop for the companies of tomorrow’s technology… and how you can profit from them.